The US~Observer, an investigative newspaper focusing on misconduct in finance and government, has published an article examining alleged market manipulation involving Quantum BioPharma Ltd. (QNTM). The report centers on claims of spoofing—placing orders with the intent to cancel before execution—that may have artificially depressed the company's stock price. These allegations are part of a $700 million-plus lawsuit currently before the U.S. District Court for the Southern District of New York (Case No. 1:24-cv-07972).
Investigative reporter Michael Quiel details that the investigation targets Andrea Nalyzyty, CIBC's chief compliance officer since at least 2015. According to the article, hundreds of alleged spoofing episodes involving millions of trading orders may have influenced the market for Quantum BioPharma shares during a critical period when the company was advancing research on Lucid-MS, an experimental therapy for multiple sclerosis. The alleged manipulation could have hindered the company's ability to raise capital and fund medical innovation.
The article also highlights a series of regulatory penalties imposed on CIBC entities during Nalyzyty's tenure. These include enforcement actions by Canadian and U.S. regulators for supervisory, reporting, and compliance failures. The US~Observer states that its investigation is part of a broader mission to examine financial misconduct and regulatory oversight issues that affect investors, market integrity, and companies seeking to fund medical innovation.
The lawsuit and the newspaper's findings raise questions about the effectiveness of compliance oversight at major financial institutions. The US~Observer encourages individuals with additional information regarding market manipulation affecting Quantum BioPharma to contact them confidentially through their website at Uso.live.
